The increase in brain cancer worldwide and the rise in cigarette smokers boost the growth of the global brain cancer diagnostics market.
The term "primary brain tumor" refers to a tumor that begins in the brain. Cancer of the brain and nervous system is the tenth highest cause of mortality in men and women. According to the American Society of Clinical Oncology (ASCO), in 2021, around 24,530 adults (13,840 men and 10,690 women) were diagnosed with primary cancerous tumors of the brain and spinal cord in the US. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Brain tumors can be fatal, severely impact the quality of life, and ultimately transform a patient's and their family's lives.


List of Companies:
1. THERMO FISHER SCIENTIFIC INC 11. KITZ HEIDELBERG
2. Siemens Healthineers AG 12. GENPATH
3. GE Healthcare 13. NVIDIA CORPORATION
4. MDxHealth 14. ONCORA MEDICAL
5. NantOmics 15. BIOMIND
6. Biocept, Inc. 16. SOPHIA AND ONCODNA
7. Koninklijke Philips N.V. 17. Clinspec Diagnostics
8. Canon Medical Systems 18. Raindance Technologies, Inc
9. Hitachi, Ltd 19. ROCHE DIAGNOSTICS
10. Neusoft Medical Systems 20. Illumina, Inc.

Similarly, Cancer Research UK estimated that around 12,288 new cases of brain, other CNS, and intracranial tumors are diagnosed in the UK each year, which makes it around 34 cases per day (2016-2018). Brain tumors, other central nervous systems, and intracranial tumors are the ninth most common malignancies in the UK, accounting for 3% of all new cancer cases (2016-2018). Also, it is the 7th most common cancer in females in the UK, with around 6,400 new cases during 2016-2018. Similarly, in males, brain, other CNS, and intracranial tumors are the 11th most common cancer, with about 5,800 new cases in the UK during 2016-2018. Incidence rates for brain tumors are highest in people aged 85 to 89 (2016-2018) in the UK.

According to the American Association of Neurological Surgeons, glioblastoma is the most common malignant brain and other CNS tumor, accounting for 47.7% of all cases; the incidence of glioblastoma is 3.21 per 100,000 people. According to Cancer Australia, around 1,879 new cases of brain cancer were diagnosed in Australia in 2020.

Early detection of tumors often provides more treatment options. Advanced imaging technology can pinpoint the location of brain tumors. Intraoperative MRI can also be used to guide tissue biopsy and tumor resection during surgery. Magnetic resonance spectroscopy (MRS) is used to examine the chemical characteristics of tumors. Thus, the increase in the prevalence of brain cancer worldwide highly demands brain cancer diagnostic tools.

The COVID-19 pandemic diverted resources from healthcare services for patients with diseases such as cancer. The brain cancer diagnostics market witnessed some shortfall at the beginning of the COVID-19 crisis owing to factors such as disruption in the supply chain and demand due to the lack of lockdown announced by most countries. Patients with cancer were negatively impacted during the COVID-19 pandemic, as many of these individuals were immunosuppressed and of older age. Additionally, cancer follow-up or imaging appointments were delayed in many clinics worldwide. Postponement of routine screening examinations resulted in delays in new cancer diagnoses. A delay in cancer diagnosis due to the COVID-19 pandemic resulted in an increase in cancer-related mortality. Studies on COVID-19 in patients with cancer were limited but consistently indicate that this population is at risk for more severe COVID-19 illness. Recent studies also suggest that pediatric patients with cancer have a lower risk of severe COVID-19 illness than adults. Thus, the pandemic had a negative impact on the growth of the brain cancer diagnostics market.


Based on diagnostics type, the brain cancer diagnostics market is segmented into imaging test, lumbar puncture, biopsy, molecular testing, platform & services, cerebral arteriogram, neurological & hearing tests/neurocognitive assessments, electroencephalography (EEG), and others. Molecular testing segment further sub-segmented into MRI, CT scan, PET, and others. Platform & services segment is further sub-segmented into sample slide, autosampler unit, solutions and platform, and services. In 2022, the imaging test segment is expected to have the largest market share. Moreover, the platform and services market for this segment is estimated to grow at the fastest CAGR during the forecast period.

Based on cancer type, the brain cancer diagnostics market is segmented into acoustic neuroma, astrocytomas, craniopharyngiomas, ganglioneuromas, glioblastoma multiforme, ganglioneuroma, meningiomas, ependymomas, oligodendroglioma, low-grade tumors, and others. In 2022, the glioblastoma multiforme segment is estimated to hold the largest market share. The same segment is expected to register the highest CAGR from 2022 to 2028.

TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 By Diagnostic Type
1.3.2 By y Cancer Type
1.3.3 By End User
1.3.4 By Tumor Size
1.3.5 By Geography
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East and Africa PEST Analysis
4.2.5 South and Central America PEST Analysis
4.3 Experts Opinion
5. Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Brain Cancer Worldwide
5.1.2 Rise in Cigarette Smokers
5.2 Market Restraints
5.2.1 High Cost of Brain Tumor Diagnosis
5.3 Market Opportunities
5.3.1 Increasing R&D for Developing Advance Technology
5.4 Future Trends
5.4.1 Advancement in Brain Tumor Diagnosis
5.5 Impact Analysis
6. Global Analysis
6.1 Revenue Forecast And Analysis
6.1.1 Revenue Forecast And Analysis
6.1.2 Market Potential Analysis, By Region
6.2 Market Positioning Analysis Of Key Players In Brain Cancer Diagnostics Market
6.2.1 Company Analysis
6.2.2 Growth Strategy Analysis
6.2.3 Performance Of Key Players
6.2.3.1 Koninklijke Philips N.V.
6.2.3.2 GE Healthcare
7. Revenue and Forecasts To 2028- by Diagnostic Type
8. Revenue and Forecasts To 2028 - Cancer Type
9. Revenue and Forecasts To 2028 - Tumor Size
10. Revenue and Forecasts To 2028 - End User
11. Revenue and Forecast to 2028 - by Geography
Continued…

About Us:
Premium Market Insights is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost-effective research reports and solutions from various publishers.
The market research industry has changed in last decade. As corporate focus has shifted to niche markets and emerging countries, a number of publishers have stepped in to fulfil these information needs. We have experienced and trained staff that helps you navigate different options and lets you choose best research solution at most effective cost.
Premium Market Insights has an extensive coverage of industry reports, company reports and country reports across all industries. In case your research needs are not met by syndicated reports offered by leading publishers, we can help you by offering a customized research solution by liaising with different research agencies saving your valuable time and money.
We provide best in class customer service and our customer support team is always available to help you on your research queries. Our commitment to customer service is best exemplified by free analyst support that we offer to our clients which sets us apart from any other provider. We also offer enterprise subscriptions which provide significant cost savings to our clients.

Contact Us:
If you have any queries about this report or if you would like further information, please
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email: [email protected]